|
PE Week Wire on Alimera Series C
PE Week Wire
March 17, 2008Alimera Sciences Inc., an Atlanta-based ophthalmic pharma company, has raised $30 million in Series C funding. Return backers include BA Venture Partners, Domain Associates, Intersouth Partners, Polaris Venture Partners and Venrock. The capital will enable Alimera to acquire a majority stake in its Phase III investigative treatment for diabetic macular edema, from development partner pSivida Ltd. Alimera last year raised a $31.8 million Series B round, and sold its OTC allergy franchise to Bausch & Lomb. Get more info.
|
